Market Brief: Orthobiologics Market Will See Modest Growth By 2024, Stimulated By Growth Factors
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
You may also be interested in...
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
BD believes the independent new company will create shareholder value and is part of the BD 2025 growth strategy.
Omron is implementing its new VitalSight platform to physicians, hospitals for remote monitoring of high-risk hypertension patients at 50 US institutions and internationally.